Related Experiment Video
Updated: Jun 5, 2025
08:25
Identification of Circular RNAs using RNA Sequencing
Published on: November 14, 2019
12.1K
Circular RNA CDR1as/ciRS-7- a novel biomarker in solid tumors
Yun Zhang1,2, Chanyu Xiong1, Zhilin Jiang1
1Sichuan Provincial Key Laboratory for Human Disease Gene Study, Genome Sequencing Center, Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Frontiers in Oncology
|December 16, 2024
Summary
High CDR1as/ciRS-7 expression indicates poor prognosis in solid tumors, correlating with larger tumor size and advanced stages. This circular RNA may serve as a crucial prognostic biomarker for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Circular RNA CDR1as/ciRS-7 is implicated as an oncogenic regulator in diverse cancers.
- The prognostic significance of CDR1as/ciRS-7 expression in solid tumors requires further clarification.
Purpose of the Study:
- To conduct an updated meta-analysis investigating the association between CDR1as/ciRS-7 expression and clinical outcomes in solid tumors.
Main Methods:
- Systematic literature search across PubMed, EMBASE, Web of Science, and Ovid databases.
- Pooled hazard ratios (HRs) and odd ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess correlations.
- Included 17 studies encompassing 2424 patients diagnosed between 2017 and 2023.
Main Results:
- Elevated CDR1as/ciRS-7 expression predicted poor overall survival (OS) across 12 solid tumor types (HR=1.93).
- Significant associations were found with larger tumor size (OR=2.11), advanced TNM stage (OR=2.05), lymph node metastasis (OR=1.74), and distant metastasis (OR=2.79).
- Stratified analyses revealed negative correlations in digestive and respiratory cancers.
Conclusions:
- Increased CDR1as/ciRS-7 expression is linked to adverse clinical characteristics and shorter OS in solid tumors.
- CDR1as/ciRS-7 shows potential as an independent prognostic biomarker for solid tumors.
